2026-06-27T12:26:29Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/948312025-03-18T14:31:55Zcom_20.500.14352_14col_20.500.14352_15

Garrido Novelle, Marta Ali, Ahmed Diéguez, Carlos Bernier, Michel De Cabo, Rafael 2024-01-23T15:22:33Z 2024-01-23T15:22:33Z 2016 Novelle, Marta G., et al. «Metformin: A Hopeful Promise in Aging Research». Cold Spring Harbor Perspectives in Medicine, vol. 6, n.o 3, marzo de 2016, p. a025932. https://doi.org/10.1101/cshperspect.a025932. 10.1101/cshperspect.a025932 https://hdl.handle.net/20.500.14352/94831 2157-1422 https://doi.org/10.1101/cshperspect.a025932 Even though the inevitable process of aging by itself cannot be considered a disease, it is directly linked to life span and is the driving force behind all age-related diseases. It is an undisputable fact that age-associated diseases are among the leading causes of death in the world, primarily in industrialized countries. During the last several years, an intensive search of antiaging treatments has led to the discovery of a variety of drugs that promote health span and/or life extension. The biguanide compound metformin is widely used for treating people with type 2 diabetes and appears to show protection against cancer, inflammation, and age-related pathologies. Here, we summarize the recent developments about metformin use in translational aging research and discuss its role as a potential geroprotector. eng restricted access Metformin: A hopeful promise in aging research journal article